$23.43+0.57 (+2.49%)
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. in the Healthcare sector is trading at $23.43. Wall Street consensus targets $29.29 (7 analysts), implying a +25.0% move over the next 12 months. The stock is currently 15% below its 52-week high of $27.64, remaining 0.8% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupiva...
Pacira Biosciences Inc (NASDAQ:PCRX) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to pop more than 20% from its current level. Pacira Biosciences Inc (NASDAQ:PCRX) reported its Q1 2026 results on April 30. It said revenue jumped 5% YoY to $177.4 […]
Nomad Foods is a leading European frozen foods producer with a broad portfolio of well-known brands sold across major supermarket chains.
The subdued stock price reaction suggests that Pacira BioSciences, Inc.'s ( NASDAQ:PCRX ) strong earnings didn't offer...
Pacira BioSciences (PCRX) has just combined a fresh set of quarterly numbers with new real world data on its lead non opioid pain drug, EXPAREL. Together, these developments give you several angles to assess the stock. See our latest analysis for Pacira BioSciences. The fresh EXPAREL study and first quarter update arrive as Pacira’s 30 day share price return of 7.67% and 90 day gain of 15.17% contrast with a 1 year total shareholder return decline of 7.60%. This signals improving short term...
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.